Streetbeat News

Revenues

NTWK

NETSOL Technologies, Inc. (NASDAQ:NTWK) has signed a $16 million, five-year agreement with a major automaker to enhance its US dealership operations using NETSOL's Otoz digital retail platform.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:32 pm

DRIO

DarioHealth Corp. (DRIO) has expanded its GLP-1 solution client base by securing a new employer contract. The financial terms of the deal were not disclosed. Dario's behavior change solutions are gaining traction in the employer, payer, and pharmaceutical markets.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:32 pm

SPY

XRT

Core Retail Sales for June increased by 0.4%, surpassing the estimated 0.1%.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:30 pm

SPY

USA Retail Sales for June remained flat at 0.0%, which is better than the estimated -0.3% but lower than the prior month's 0.1%.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:30 pm

MS

Morgan Stanley's CFO announced that the bank is on track to reach its $10 trillion client asset target. Additionally, the investment banking business is in the early stages of recovery.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:27 pm

PGR

Progressive reported Q2 2024 GAAP EPS of $2.48, significantly beating the estimate of $1.76. The company also reported net premiums written of $17.9 billion.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:21 pm

VTAK

Catheter Precision, Inc. (NYSE:VTAK) has completed the patient follow-up phase for the VIVO European Registry, which began in October 2021 and concluded patient enrollment in June 2023. The data collected will fulfill European regulatory requirements and aid in future studies and improvements to the VIVO technology. The data is expected to be available in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:19 pm

LSTA

Lisata Therapeutics has completed enrollment in its Phase 2a BOLSTER trial for certepetide in first-line cholangiocarcinoma nearly six months ahead of schedule. Top-line data is expected by mid-2025, and a second-line cholangiocarcinoma arm has been added to the trial.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:12 pm

TKLF

Yoshitsu Co (NASDAQ:TKLF) reported a significant improvement in its financial performance for the fiscal year, with earnings per share (EPS) rising to $0.20 from a loss of $(0.22) year-over-year. Sales also increased by 15.29% to $195.68 million from $169.72 million.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:08 pm

ONVO

Organovo presented its outlook and plans at the Jones Trading Healthcare Conference, highlighting the progress and upcoming Phase 2a trial of FXR314 for IBD. The company encouraged a review of the FXR314 presentation amid strong M&A activity in the IBD sector.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 12:07 pm